Recent Japanese case reports of ketosis and ketoacidosis have reignited concerns about the safety of glucagon‑like peptide‑1 (GLP‑1)‑based medications when they are used without proper medical oversight. An editorial published in Diabetology International examines the clinical and regulatory dimensions of inappropriate GLP‑1 use, emphasizing that the problem extends beyond off‑label prescribing to unsafe weight‑loss practices.
Clinical picture of the Japanese cases
Three young women, aged 21 or 23, were hospitalized in Japan after developing ketosis or ketoacidosis while using tirzepatide, a GLP‑1/GIP dual agonist. None of the patients had type 2 diabetes, and two were not obese at the time of presentation. The third, initially obese, had followed a carbohydrate‑restricted diet and became non‑obese before ketoacidosis emerged. In two cases, ketoacidosis occurred at the lowest tirzepatide dose; in the third, it appeared after dose escalation. The editorial notes that none of the patients received documented nutritional counseling or other forms of medical supervision.
Regulatory context and misuse of GLP‑1 drugs
In Japan, the anti‑obesity agents Wegovy and Zepbound are reimbursed only when prescribed by specialized institutions after a structured six‑month lifestyle‑intervention program. By contrast, Mounjaro—a tirzepatide formulation approved for type 2 diabetes—does not carry the same prescribing restrictions, despite containing the same active molecule as Zepbound. This regulatory gap, the authors argue, may facilitate illegal resale of tirzepatide for cosmetic weight loss, a practice reported in Japanese media.
Beyond the illicit market, the editorial highlights broader patterns of inappropriate use, such as acquiring GLP‑1 agents through unofficial channels or online prescriptions. Such practices bypass both medical appropriateness—balancing benefits against risks—and regulatory appropriateness, which ensures compliance with reimbursement policies and legal requirements.
Risks beyond known drug side effects
While gastrointestinal symptoms like nausea, diarrhea, and constipation are well‑documented adverse effects of GLP‑1 therapies, the Japanese cases illustrate additional hazards linked to extreme dietary restriction combined with pharmacologic appetite suppression. The authors suggest that severe metabolic complications, including ketoacidosis, may stem more from unsafe weight‑loss regimens than from intrinsic drug toxicity, though the latter remains a concern.
Weight loss achieved through severe calorie restriction carries inherent biological risks, particularly when it leads to undernutrition. The editorial references the newly proposed “female underweight/undernutrition syndrome” (FUS) to underscore that underweight status itself can precipitate significant physical and psychological consequences. Accordingly, appropriate weight‑loss strategies should integrate realistic targets, adequate nutrition, and continuous medical monitoring.
In conclusion, the authors call for a shift in discourse from merely discouraging off‑label GLP‑1 prescriptions to promoting “appropriate weight reduction.” They argue that success should be measured not only by the amount of weight lost but also by the safety and nutritional adequacy of the process. Enhanced supervision, structured dietary guidance, and adherence to regulatory frameworks are presented as essential components to prevent further cases like those reported in Japan.
Mitchell Landsberg is a Senior Technology Correspondent at News Raise. He covers consumer electronics, artificial intelligence, software developments, and digital privacy trends.
